NDAINJECTIONINJECTABLE
Approved
Sep 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 1h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MEZLIN (mezlocillin sodium monohydrate) is an injectable penicillin-class antibiotic approved in 1981 for treating bacterial infections via parenteral administration. As an extended-spectrum penicillin, it provides broader gram-negative coverage than older penicillins, making it suitable for serious infections in hospitalized patients.
LOE Approaching
LOE-stage product with moderate competitive pressure (30/100) indicates declining market relevance and likely reduced team headcount and promotional investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
MEZLIN offers limited career upside as a mature, legacy injectable antibiotic in LOE stage with zero linked job opportunities. Roles supporting this product focus on operational excellence, regulatory compliance, and controlled market transition rather than revenue growth or innovation.
Supply Chain ManagerRegulatory Specialist
Worked on MEZLIN at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.